Quick Answer
CG Oncology, Inc. reported Net Income of -$161.00 million for fiscal year 2025.
CG Oncology, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$161.00M | -82.9% |
| 2024 | -$88.04M | -81.1% |
| 2023 | -$48.61M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$43.81M | -114.7% | -5.8% |
| June 30, 2025 | -$41.43M | -119.2% | -20.2% |
| March 31, 2025 | -$34.45M | -103.4% | -68.8% |
| September 30, 2024 | -$20.41M | -73.4% | -8.0% |
| June 30, 2024 | -$18.90M | -62.8% | -11.6% |
| March 31, 2024 | -$16.93M | -95.3% | -43.9% |
| September 30, 2023 | -$11.77M | — | -1.3% |
| June 30, 2023 | -$11.61M | — | -33.9% |
- CG Oncology, Inc. showed a decrease of -82.9% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, CG Oncology, Inc.’s net income has declined by 231.2% (from -$48.61 million to -$161.00 million).
- The most recent figure is from CG Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: